Table 3.
Grade 3 and 4 Adverse Events at Least Possibly Related to Pazopanib1
| Group A normal |
Group B mild |
Group C Moderate |
Group D severe |
Total | ||||
|---|---|---|---|---|---|---|---|---|
| Dose of pazopanib (mg) | 800 | 400 | 800 | 200 | 400 | 100 | 200 | |
| Number of patients (%) | 23 (100) | 9 (100) | 14 (100) | 13 (100) | 6 (100) | 13 (100) | 19 (100) | 97 (100) |
| Hematologic | ||||||||
| Lymphopenia | 1(4) | 2 (14) | 1 (17) | 1 (8) | 5 (5) | |||
| Neutrophil count decreased | 1 (7) | 1 (1) | ||||||
| Platelet count decreased | 1 (8) | 1 (1) | ||||||
| Gastrointestinal disorders | ||||||||
| Abdominal Pain | 1 (8) | 1 (1) | ||||||
| Colitis | 1 (7) | 1 (1) | ||||||
| Diarrhea | 2 (11) | 2 (2) | ||||||
| Fistula – Abdomen NOS | 1 (7) | 1 (1) | ||||||
| Nausea | 1 (11) | 1 (7) | 1 (8) | 3 (3) | ||||
| Vomiting | 1 (4) | 1 (7) | 1 (8) | 3 (3) | ||||
| Coagulation | ||||||||
| Partial Thromboplastin Time | 1 (8) | 1 (1) | ||||||
| Constitutional | ||||||||
| Anorexia | 1 (11) | 1 (17) | 2 (2) | |||||
| Dyspnea | 1 (4) | 1 (1) | ||||||
| Fatigue | 3 (13) | 1 (8) | 1 (17) | 4 (31) | 1 (5) | 10 (10) | ||
| Muscle Weakness | 1 (8) | 1 (1) | ||||||
| Liver dysfunction | ||||||||
| Alanine aminotransferase increased | 1 (11) | 1 (8) | 2 (33) | 4 (4) | ||||
| Alkaline phosphatase increased | 2 (22) | 1 (8) | 1 (8) | 1 (5) | 5 (5) | |||
| Aspartate aminotransferase increased | 3 (33) | 1 (8) | 2 (33) | 2 (15) | 3 (16) | 11 (11) | ||
| Blood bilirubin increased | 1 (11) | 4 (31) | 1 (17) | 2 (15) | 2 (11) | 10 (10) | ||
| Metabolic and other | ||||||||
| Hypokalemia | 1 (5) | 1 (1) | ||||||
| Hyponatremia | 1 (11) | 2 (15) | 3 (3) | |||||
| Hypophosphatemia | 1 (11) | 1 (8) | 1 (5) | 3 (3) | ||||
| Hyperkalemia | 1 (11) | 1 (1) | ||||||
| Hypertension | 1 (4) | 1 (11) | 1 (7) | 2 (15) | 5 (5) | |||
1
Maximum grade for all cycles in a given patient